LASA Supergenerics Limited has announced a key leadership appointment, with the Board of Directors approving the appointment of Mr. Ganesh Suresh Potdar as Additional Director in the capacity of Executive Director and Occupier of all company units. The decision was made during a board meeting held on January 02, 2026, which commenced at 2:00 p.m. and concluded at 4:00 p.m.

Board Meeting Outcome

The appointment was approved pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. However, the appointment remains subject to approval by members at the ensuing General Meeting or Postal Ballot of the company.

Director Profile and Expertise

Mr. Ganesh Suresh Potdar brings significant operational and commercial expertise to his new role. The following table outlines his key credentials:

Professional Background

Mr. Potdar brings a broad-based understanding of business operations and commercial practices to LASA Supergenerics. His professional expertise includes:

• Exposure to banking-related processes and coordination with financial institutions
• Understanding of routine banking formalities and compliance requirements
• Experience in documentation and compliance-related interactions
• Capability to contribute in financial coordination and operational follow-up matters

Corporate Governance Details

As per the disclosure requirements, Mr. Potdar currently holds no directorships in other public companies (excluding foreign, private, and Section 8 companies). He also has no memberships or chairmanships of Audit and Stakeholders' Relationships Committees across public companies. There are no inter-se relationships between Mr. Potdar and other directors of the company.

Regulatory Compliance

The appointment follows all regulatory requirements under SEBI guidelines. The company has made the information available on its website at www.lasalabs.com and on stock exchange websites. The appointment notification was signed by Omkar Herlekar, Chairman and Managing Director of LASA Supergenerics Limited.

Lasa Supergenerics Limited has announced a key leadership appointment, naming Mrs. Mitti Jain as the company's new Company Secretary and Compliance Officer. The appointment takes effect from December 16, 2025, and was communicated to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details

Lasa Supergenerics has appointed Mrs. Jain pursuant to Section 203 of the Companies Act, 2013 and Regulation 6(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. She will also serve as Key Managerial Personnel of the company.

Professional Background

Mrs. Mitti Jain brings substantial expertise to her new role at Lasa Supergenerics, with 10 years of rich experience in corporate laws and allied matters. She is an Associate Member of the Institute of Company Secretaries of India (ICSI), demonstrating her professional qualifications in corporate governance and compliance matters.

Educational and Professional Credentials

• Professional Qualification: Associate Member of Institute of Company Secretaries of India
• Educational Background: B.Com and M.Com degrees from University of Gujarat
• Experience: 10 years of experience in corporate law

Regulatory Compliance

The appointment announcement was made in compliance with SEBI circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015. The company has fulfilled its disclosure obligations by informing both BSE Limited and National Stock Exchange of India Limited about this key managerial appointment.

The information regarding this appointment is also available on the company's website at www.lasalabs.com and on the stock exchange websites. This appointment strengthens Lasa Supergenerics' corporate governance framework with an experienced professional overseeing compliance and secretarial functions.